Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis

BMC Medicine

Joshua F Yarrow⁴  Anita Wokhlu²  Huanguang Jia⁵  Fan Ye⁴  Baiming Zou¹  Jonathan J Shuster³  Stephen E Borst⁴ 

[1] Department of Biostatistics, University of Florida, Gainesville, USA;Department of Medicine-Cardiovascular Division, University of Florida, Gainesville, USA;Department of Health Outcomes and Policy, University of Florida, Gainesville, USA;Department of Applied Physiology & Kinesiology, University of Florida, Gainesville, USA;Research Service, Malcom Randall VA Medical Center, Gainesville, FL, USA

关键词: Meta-analysis;    Random effects;    Cardiovascular disease trials;    DHT;    Testosterone;   

Others  :  1118147
DOI  :  10.1186/s12916-014-0211-5

 received in 2014-09-09, accepted in 2014-10-14,  发布年份 2014

【 摘 要 】

Background

Potential cardiovascular (CV) risks of testosterone replacement therapy (TRT) are currently a topic of intense interest. However, no studies have addressed CV risk as a function of the route of administration of TRT.

Methods

Two meta-analyses were conducted, one of CV adverse events (AEs) in 35 randomized controlled trials (RCTs) of TRT lasting 12 weeks or more, and one of 32 studies reporting the effect of TRT on serum testosterone and dihydrotestosterone (DHT).

Results

CV risks of TRT: Of 2,313 studies identified, 35 were eligible and included 3,703 mostly older men who experienced 218 CV-related AEs. No significant risk for CV AEs was present when all TRT administration routes were grouped (relative risk (RR) = 1.28, 95% confidence interval (CI): 0.76 to 2.13, P = 0.34). When analyzed separately, oral TRT produced significant CV risk (RR = 2.20, 95% CI: 1.45 to 3.55, P = 0.015), while neither intramuscular (RR = 0.66, 95% CI: 0.28 to 1.56, P = 0.32) nor transdermal (gel or patch) TRT (RR = 1.27, 95% CI: 0.62 to 2.62, P = 0.48) significantly altered CV risk. Serum testosterone/DHT following TRT: Of 419 studies identified, 32 were eligible which included 1,152 men receiving TRT. No significant difference in the elevation of serum testosterone was present between intramuscular or transdermal TRT. However, transdermal TRT elevated serum DHT (5.46-fold, 95% CI: 4.51 to 6.60) to a greater magnitude than intramuscular TRT (2.20-fold, 95% CI: 1.74 to 2.77).

Conclusions

Oral TRT produces significant CV risk. While no significant effects on CV risk were observed with either injected or transdermal TRT, the point estimates suggest that further research is needed to establish whether administration by these routes is protective or detrimental, respectively. Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route, as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies.

【 授权许可】

   
2014 Borst et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S: Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013, 9:414-424.
• [2]Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM: Testosterone use in men and its effects on bone health: A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metabol 2006, 91:2011-2016.
• [3]Traish AM: Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids 2014, 88:117-126.
• [4]Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451-1457.
• [5]Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM: Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:2560-2575.
• [6]Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM: Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:29-39.
• [7]Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S: Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
• [8]Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310:1829-1836.
• [9]Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014, 9:e85805.
• [10]Xu L, Freeman G, Cowling BJ, Schooling CM: Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013, 11:108. BioMed Central Full Text
• [11]Shuster JJ, Guo JD, Skyler JS: Meta-analysis of safety for low event-rate binomial trials. Res Synth Meth 2012, 3:ᅟ. doi:10.1002/jrsm.1039
• [12]Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M: Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014, 13:1327-1351.
• [13][http:/ / www.fda.gov/ safety/ medwatch/ safetyinformation/ safetyalertsforhumanmedicalproducts / ucm384225.htm] webcite Testosterone Products: Drug Safety Communication - FDA Investigating Risk of Cardiovascular Events. 31 January 2014. []
• [14][http:/ / www.pbm.va.gov/ PBM/ vacenterformedicationsafety/ nationalpbmbulletin/ Testosterone_Products_and_Cardiovas cular_Safety_NATIONAL_PBM_BULLETIN_ 02.pdf] webcite Department of Veterans Affairs VHA Pharmacy Benefits Management Advisory Panel: Testosterone Products and Cardiovascular Safety. 7 February 2014. []
• [15][https:/ / www.endocrine.org/ membership/ email-newsletters/ endocrine-insider/ 2014/ february-20-2014/ society-statement-risk-of-cardiovas cular-events-in-men-receiving-testo sterone-therapy-available] webcite Endocrine Society Statement on the Risk of Cardiovascular Events in Men Receiving Testosterone Therapy Available. In []
• [16]Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM: Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012, 97:2050-2058.
• [17]English KM, Steeds RP, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000, 102:1906-1911.
• [18]Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA: Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012, 5:315-321.
• [19]Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, Lin YL, Goodwin JS: Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014, 48:1138-1144.
• [20]Inui S, Itami S: Androgen actions on the human hair follicle: perspectives. Exp Dermatol 2013, 22:168-171.
• [21]Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993, 92:903-910.
• [22]Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, Hirsch CH, Cappola AR, Matsumoto AM: Testosterone, dihydrotestosterone and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab 2014, 99:2061-2068.
• [23]Shores MM, Arnold AM, Biggs ML, Longstreth WT Jr, Smith NL, Kizer JR, Cappola AR, Hirsch CH, Marck BT, Matsumoto AM: Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Clin Endocrinol (Oxf) 2014, 81:746-753.
• [24]Yarrow JF, Beck DT, Conover CF, Beggs LA, Goldberger BA, Borst SE: Invalidation of a commercially available human 5alpha-dihydrotestosterone immunoassay. Steroids 2013, 78:1220-1225.
• [25]Gooren LJ, Saad F, Haide A, Yassin A: Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels. Andrologia 2008, 40:298-302.
• [26]Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
• [27]Borenstein M, Hedges LV, Higgins J, Rothstein HR: A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Meth 2010, 1:97-111.
• [28]Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0. Wiley Publications, Chichester, UK; 2011.
• [29]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [30]Hedges LV, Vevea JL: Fixed - and random-effects models in meta-analysis. Psychol Methods 1998, 3:486-504.
• [31]Shuster JJ: Empirical vs natural weighting in random effects meta-analysis. Stat Med 2010, 29:1259-1265.
• [32]Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503-510.
• [33]Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G: Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010, 7:3495-3503.
• [34]Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ: Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab 2014, 306:E433-E442.
• [35]Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM: Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009, 54:919-927.
• [36]Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ: Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002, 282:E601-E607.
• [37]Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A: The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014, 68:203-215.
• [38]Hall GM, Larbre JP, Spector TD, Perry LA, Da Silva JA: A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996, 35:568-573.
• [39]Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, Zainuddin ZM, Tan HM: A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012, 110:260-265.
• [40]Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY: Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012, 167:531-541.
• [41]Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F: Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010, 73:602-612.
• [42]Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S: Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004, 59:75-78.
• [43]Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C: Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-1667.
• [44]Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R: Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004, 98:906-913.
• [45]Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R: Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008, 20:378-387.
• [46]Sheffield-Moore M, Dillon EL, Casperson SL, Gilkison CR, Paddon-Jones D, Durham WJ, Grady JJ, Urban RJ: A randomized pilot study of monthly cycled testosterone replacement or continuous testosterone replacement versus placebo in older men. J Clin Endocrinol Metab 2011, 96:E1831-E1837.
• [47]Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, Khoo EM, Lee G, Lee BC, Lee V, Tan HM: Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int 2013, 111:1130-1140.
• [48]Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ: Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006, 47:251-262.
• [49]Glintborg D, Christensen LL, Kvorning T, Larsen R, Brixen K, Hougaard DM, Richelsen B, Bruun JM, Andersen M: Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men. Mediators Inflamm 2013, 2013:539156.
• [50]Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, Wolfe P, Kohrt WM, Ruscin JM, Kittelson J, Cress ME, Ballard R, Schwartz RS: Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013, 98:1891-1900.
• [51]Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828-837.
• [52]Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ: Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011, 8:2079-2089.
• [53]Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 58:1134-1143.
• [54]Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, Sjostrom L, Holm G, Bjorntorp P: Androgen treatment of abdominally obese men. Obes Res 1993, 1:245-251.
• [55]Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, Mazer NA, Knapp PE, Hanka S, Lakshman KM, Ulloor J, Zhang A, Orwoll K, Eder R, Collins L, Mohammed N, Rosen RC, DeRogatis L, Bhasin S: Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012, 157:681-691.
• [56]Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC: Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
• [57]Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS: Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006, 27:57-64.
• [58]Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F, Ross RJ: Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 2006, 29:381-391.
• [59]Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD: DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-1659.
• [60]Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL: Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001, 111:255-260.
• [61]Chapman IM, Visvanathan R, Hammond AJ, Morley JE, Field JB, Tai K, Belobrajdic DP, Chen RY, Horowitz M: Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009, 89:880-889.
• [62]Testosterone treatment of men with alcoholic cirrhosis: a double-blind study: the Copenhagen Study Group for Liver Diseases.Hepatology 1986, 6:807–813.
• [63]Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008, 299:39-52.
• [64]Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM: Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009, 160:821-831.
• [65]Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997, 47:727-737.
• [66]Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S: Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012, 307:931-939.
• [67]Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, Mazer NA, Bhasin S: The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010, 95:3955-3964.
• [68]Raynaud JP, Legros JJ, Rollet J, Auges M, Bunouf P, Sournac M, Fiet J: Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. J Steroid Biochem Mol Biol 2008, 109:168-176.
• [69]Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003, 60:21-28.
• [70]Wang C, Harnett M, Dobs AS, Swerdloff RS: Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 2010, 31:457-465.
• [71]Cherrier MM, Craft S, Matsumoto AH: Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl 2003, 24:568-576.
• [72]Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, Liao CH: Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007, 19:411-417.
• [73]Dean JD, Carnegie C, Rodzvilla J, Smith T: Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol 2004, 6:S22-S29.
• [74]Di Luigi L, Sgro P, Aversa A, Migliaccio S, Bianchini S, Botre F, Romanelli F, Lenzi A: Concerns about serum androgens monitoring during testosterone replacement treatments in hypogonadal male athletes: a pilot study. J Sex Med 2012, 9:873-886.
• [75]Juang PS, Peng S, Allehmazedeh K, Shah A, Coviello AD, Herbst KL: Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. J Sex Med 2014, 11:563-573.
• [76]Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B, Bs RN: Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005, 2:213-226.
• [77]Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM: Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011, 186:191-197.
• [78]Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000, 85:4500-4510.
• [79]Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000, 85:964-969.
• [80]Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A: Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011, 75:836-843.
• [81]Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M, Demers LM: Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988, 66:546-551.
• [82]Bals-Pratsch M, Langer K, Place VA, Nieschlag E: Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol 1988, 118:7-13.
• [83]Behre HM, von Eckardstein S, Kliesch S, Nieschlag E: Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999, 50:629-635.
• [84]Cunningham GR, Cordero E, Thornby JI: Testosterone replacement with transdermal therapeutic systems: physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989, 261:2525-2530.
• [85]Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992, 74:623-628.
• [86]Franchimont P, Kicovic PM, Mattei A, Roulier R: Effects of oral testosterone undecanoate in hypogonadal male patients. Clin Endocrinol (Oxf) 1978, 9:313-320.
• [87]Roth MY, Dudley RE, Hull L, Leung A, Christenson P, Wang C, Swerdloff R, Amory JK: Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5alpha-reductase by finasteride. Int J Androl 2011, 34:541-547.
• [88]van Coevorden A, Stolear JC, Dhaene M, van Herweghem JL, Mockel J: Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 1986, 26:48-54.
• [89]Yarrow JF, McCoy SC, Borst SE: Intracrine and myotrophic roles of 5alpha-reductase and androgens: a review. Med Sci Sports Exerc 2012, 44:818-826.
• [90]Stanczyk FZ, Azen CG, Pike MC: Effect of finasteride on serum levels of androstenedione, testosterone and their 5alpha-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol 2013, 138:10-16.
• [91]Wang C, Shiraishi S, Leung A, Baravarian S, Hull L, Goh V, Lee PW, Swerdloff RS: Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: interference and comparison with established methods. Steroids 2008, 73:1345-1352.
• [92]Schoenfeld MJ, Shortridge E, Cui Z, Muram D: Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med 2013, 10:1401-1409.
• [93]Donatucci C, Cui Z, Fang Y, Muram D: Long-term treatment patterns of testosterone replacement medications. J Sex Med 2014, 11:2092-2099.
• [94]Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, Saxton JM: Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J 2012, 164:893-901.
• [95]Empen K, Lorbeer R, Dorr M, Haring R, Nauck M, Glaser S, Krebs A, Reffelmann T, Ewert R, Volzke H, Wallaschofski H, Felix SB: Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler Thromb Vasc Biol 2012, 32:481-486.